Clinical Trials on KRAS P.G12C in United States
Total 93 results
-
Addario Lung Cancer Medical InstituteRecruiting
-
D3 Bio (Wuxi) Co., LtdRecruitingKRAS P.G12CAustralia, Korea, Republic of, China, United States, Hong Kong
-
Elicio TherapeuticsRecruitingColorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12SUnited States
-
AmgenActive, not recruitingKRAS p.G12C Mutant Advanced Solid TumorsUnited States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
-
Revolution Medicines, Inc.RecruitingNon-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, CancerUnited States
-
Lupin Ltd.CompletedA Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsNRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsUnited Kingdom, Netherlands, Belgium
-
Devalingam MahalingamAmgenWithdrawnPancreatic Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer | KRAS P.G12CUnited States
-
AmgenRecruitingAdvanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
-
ETOP IBCSG Partners FoundationMirati Therapeutics Inc.RecruitingNSCLC Stage IV | KRAS P.G12CIreland, Italy, France, Spain, United Kingdom, Belgium
-
University of UtahTerminatedKRAS and NRAS Wild-type Colorectal CancerUnited States
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS MutationSpain, United Kingdom, United States, Belgium
-
National Cancer Institute (NCI)CompletedStage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | KRAS NP_004976.2:p.G12RUnited States
-
Georgetown UniversityImmune System Key LtdRecruitingSolid Tumor | KRAS Mutation-Related TumorsUnited States
-
Cardiff OncologyPfizerRecruitingMetastatic Colorectal Cancer | CRC | KRAS/NRAS MutationUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingPancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | KRAS NP_004976.2:p.G12DUnited States
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS Mutation; SOS1United States, Netherlands, Germany
-
Boehringer IngelheimRecruitingSolid Tumor, KRAS MutationUnited States, Taiwan, Japan
-
Ryan Gentzler, MDMirati Therapeutics Inc.; University of VirginiaRecruitingAdagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesNSCLC | Non Small Cell Lung Cancer | KRAS G12CUnited States
-
Calithera Biosciences, IncCompletedNSCLC | Solid Tumors | KRAS Gene Mutation | CRCUnited States
-
University of PennsylvaniaCompleted
-
NYU Langone HealthWithdrawnAdvanced Non-small Cell Lung Cancer With KRAS G12C MutationUnited States
-
NYU Langone HealthRecruitingAdvanced Non-small Cell Lung Cancer With KRAS G12C MutationUnited States
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Turning Point Therapeutics, Inc.TerminatedAdvanced Solid Tumor | Metastatic Solid Tumor | KRAS Mutation-Related TumorsUnited States
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
Vanderbilt University Medical CenterEdwards LifesciencesCompletedColorectal Surgery | Perioperative Care | Quality Improvement | ERASUnited States
-
OnKure, Inc.Active, not recruitingMelanoma | NRAS Gene Mutation | RAS MutationUnited States
-
TheRas, IncRecruitingNSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12CUnited States, Australia
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Ikena OncologyRecruitingColorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene MutationUnited States
-
Oncolytics BiotechMontefiore Medical CenterCompletedKRAS Mutant Metastatic Colorectal CancerUnited States
-
University of UtahPfizerCompletedAdvanced KRAS Positive Metastatic Colorectal CancerUnited States
-
Elicio TherapeuticsActive, not recruitingColorectal Cancer | Ovarian Cancer | Cholangiocarcinoma | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Minimal Residual Disease | Gallbladder Carcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12RUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene MutationUnited States
-
Shirish M GadgeelAstraZeneca; Henry Ford Health SystemWithdrawnLung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating MutationUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
Affini-T Therapeutics, Inc.RecruitingColorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12VUnited States
-
Abramson Cancer Center at Penn MedicinePfizerActive, not recruitingNon-Small Cell Lung Cancer | KRAS Mutation-Related TumorsUnited States
-
Black Diamond Therapeutics, Inc.RecruitingMelanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditionsUnited States
-
David E GerberCancer Prevention Research Institute of Texas; Sagimet Biosciences Inc.Recruiting
-
University of VirginiaActive, not recruitingReal-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAFUnited States
-
Dana-Farber Cancer InstituteCompletedSolid Tumors | KRAS Mutant Non-Small Cell Lung CancerUnited States
-
Cardiff OncologyCompletedMetastatic Colorectal Cancer | KRAS Gene MutationUnited States
-
Queen Mary University of LondonAstraZeneca; Cancer Research UKUnknownSquamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRASUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | BRAF NP_004324.2:p.V600X | KRAS wt AlleleUnited States
-
Sierra Oncology, Inc.TerminatedRelapsed Metastatic KRAS-Mutated Non-Small Cell Lung CancerUnited States
-
Taiho Oncology, Inc.TerminatedNon-Small Cell Lung Cancer | KRAS Gene Mutation | Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedNon Small Cell Lung Cancer | KRAS Gene MutationUnited States
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid TumorsKorea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore